Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450

Psychopharmacology (Berl). 2004 Jan;171(2):229-30. doi: 10.1007/s00213-003-1599-3. Epub 2003 Nov 21.

Authors

H R Sumnall¹, L Jerome, R Doblin, M C Mithoefer

Affiliation

¹ Centre for Public Health, Liverpool John Moores University, 70 Great Crosshall Street, L3 2AB, Liverpool, UK. h.sumnall@livjm.ac.uk

PMID: 14634709
DOI: 10.1007/s00213-003-1599-3

No abstract available

Publication types

Comment

MeSH terms

Animals
Dopamine / metabolism*
Hallucinogens / administration & dosage*
Hallucinogens / adverse effects
Humans
Illicit Drugs / adverse effects
N-Methyl-3,4-methylenedioxyamphetamine / administration & dosage*
N-Methyl-3,4-methylenedioxyamphetamine / adverse effects
Neurotoxicity Syndromes / etiology*
Neurotoxicity Syndromes / metabolism
Parkinson Disease, Secondary / chemically induced*
Parkinson Disease, Secondary / metabolism
Primates
Psychomotor Disorders / chemically induced*
Psychomotor Disorders / metabolism
Species Specificity

Substances

Hallucinogens
Illicit Drugs
N-Methyl-3,4-methylenedioxyamphetamine
Dopamine